- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04278963
Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19
Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.
Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Decoction as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this randomized,three-arm controlled, single-blind trial will evaluate the efficacy and safety of Yinhu Qingwen Decoction (Granula) in patients hospitalized with mild or common CoVID-19 respiratory disease.
Study Overview
Status
Conditions
Detailed Description
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.
The clinical spectrum of CoVID-19 infection appears to be wide,including asymptomatic infection, mild upper respiratory disease, severe viral pneumonia with respiratory failure, and even death.However,there is no specific antiviral therapy for CoVID-19 infection, which provides a window of opportunity for testing candidate antiviral therapies. Previous experiences with SARS and MERS-CoV, highlight the need of the early intervention with Chinese medicine, and so as for CoVID-19 infection. The treatment of Chinese medicine for CoVID-19 infection suggested its benefits to improve of clinical outcomes, reduce the risk of disease progression, accelerate recovery, and reduce intensive supportive care and long-term hospitalization.
Yinhu Qingwen Decoction (Granula) consists of 11 common non-toxic traditional Chinese medicine such as Polygonum cuspidatum, Honeysuckle, Nepeta, Ligustrum lucidum. Previous vivo antiviral studies showed its activity for the inbition of CoVID-19. This clinical trial is planned to evaluate the mean clinical recovery time for patients with mild and common CoVID-19 infection as the primary outcome, and to evaluate the effect of the symptoms relief and virus clearance as well as the clinical safety.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Hubei
-
Jingzhou, Hubei, China, 434000
- Jingzhou Hospital of Traditional Chinese Medicine
-
Wuhan, Hubei, China, 430200
- Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University
-
Xiangyang, Hubei, China, 441000
- Xiangyang Hospital of Traditional Chinese Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years at time of signing Informed Consent Form.
- Laboratory (RT-PCR) confirmed infection with CoVID-19.
- Hospitalised with Fever(≥36.7℃ -axilla or oral temperature ≥ 38.0 ℃ or ≥38.6°C tympanic or rectal) and cough;
- No difficulty swallowing oral medications.
- Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study.
Exclusion Criteria:
- Allergies, known to be allergic to research drugs or drug excipients;
- Patient weight is less than 40 kg;
- Respiratory distress-RR≥30 / min on room air,or SPO2≤ 93%, or PaO2/FiO2 ≤300mmHg (1mmHg = 0.133kPa)
- Shock;
- The clinician judges that ICU monitoring treatment is needed;
- Patients who have participated in other clinical trials within 1 month;
- Known patients with impaired renal function (estimated creatinine clearance <60 mL / min (male: Cr (ml / min) = (140-age) × body weight (kg) / 72 × blood creatinine concentration (mg / dl); female: Cr (ml / min) = (140-age) × weight (kg) / 85 × blood creatinine concentration (mg / dl));
- During the screening or within 24 hours before screening, patients were found to have any of the following laboratory parameter abnormalities (based on local laboratory reference range):-ALT or AST level> 5 times the upper limit of normal range (ULN) or-ALT or AST > 3 times ULN and total bilirubin levels> 2 times ULN;
- Being pregnant or breastfeeding, or having a positive pregnancy test at the time of pre-dose inspection, or planning to become pregnant within 3 months of study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Yin Hu Qing Wen Decoction Group
Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen Decoction (Granula) for 10 days.
|
YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc.
The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
It will be given a 200ml per time, three times a day, for 10 days.
Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
|
Placebo Comparator: Yinhu Qingwen Decoction low-dose group
Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen Decoction (Granula) for 10 days.
|
Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
It will be given a 200ml per time, three times a day, for 10 days.
|
Active Comparator: Integrated Chinese and Western Medicine group
Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms.
The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into 3 times(once with 200ml).
The Chinese medicine decoction will be given 200ml per time, three times a day for 10 days.
|
Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean clinical recovery time (hours)
Time Frame: up to 28 days
|
The clinical recovery time is defined as the time from initiation of study treatment (active or placebo) until normalisation of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours. Normalisation and alleviation criteria: (1) Fever: ≤36.6°C or -axilla, ≤37.2 °C oral or ≤37.8°C rectal or tympanic;(2)Respiratory rate - ≤24/minute on room air; 3) Oxygen saturation - >94% on room air; (4) Cough - mild or absent on a patient reported scale (cough symptoms score ≤ 2 points). |
up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen
Time Frame: up to 28 days
|
up to 28 days
|
|
Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.
Time Frame: up to 28 days
|
up to 28 days
|
|
Time to defervescence (in those with fever at enrolment)
Time Frame: up to 28 days
|
up to 28 days
|
|
Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)
Time Frame: up to 28 days
|
up to 28 days
|
|
Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
Time Frame: up to 28 days
|
up to 28 days
|
|
Frequency of requirement for supplemental oxygen or non-invasive ventilation
Time Frame: up to 28 days
|
up to 28 days
|
|
Frequency of respiratory progression
Time Frame: up to 28 days
|
Defined as: SPO2≤ 93% on room air or PaO2/FiO2≤ 300mmHg and requirement for supplemental oxygen or more advanced ventilator support.
|
up to 28 days
|
Severe case incidence
Time Frame: up to 28 days
|
Severe case is defined as respiratory rate ≥30/minute on room air;or Oxygen saturation - ≤94% on room air;or PaO2/FiO2≤300mmHg.
|
up to 28 days
|
Proportion of re-hospitalization or admission to ICU
Time Frame: up to 28 days
|
up to 28 days
|
|
All-cause mortality
Time Frame: up to 28 days
|
up to 28 days
|
|
Frequency of serious adverse events
Time Frame: up to 28 days
|
up to 28 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wei Zhang, Jingzhou Hospital of Traditional Chinese Medicine
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YHQW-V3.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CoVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on YinHu QingWen Decoction
-
Zhong WangNot yet recruiting
-
Zhong WangThe First Affiliated Hospital of Dalian Medical University; North China University... and other collaboratorsSuspendedCOVID-19 | Severe Pneumonia | Chinese MedicineChina
-
Qilu Hospital of Shandong UniversityRecruitingCoronavirus | Traditional Chinese MedicineChina
-
Nanyang Technological UniversityMinistry of Health, SingaporeWithdrawn
-
Yiling Pharmaceutical Inc.Completed
-
Xinhua Hospital, Shanghai Jiao Tong University...RecruitingSepsis | Acute Lung InjuryChina
-
Guang'anmen Hospital of China Academy of Chinese...Guangdong Provincial Hospital of Traditional Chinese Medicine; Peking Union... and other collaboratorsUnknownInfertility | EndometriosisChina
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Liu LongxiaoNot yet recruiting
-
Qianfoshan HospitalRecruitingCOVID-19 PneumoniaChina